Search results
Moderna Stock Takes Minimal Hit After New COVID Vaccine Topped Projected Estimates
Black Enterprise· 17 hours agoModerna announced an increase in stock price after their COVID vaccine exceeded sales estimates for...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 20 hours agoThe company reaffirmed anticipated revenue of $4bn from its respiratory franchise. It now expects around $0.3bn in net sales for the first half of the...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 2 days agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 1 day ago“This is the start of a banner year for our vaccine platform as we continue to advance mRNA...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 1 day agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
We Think Shareholders May Want To Consider A Review Of Moderna, Inc.'s (NASDAQ:MRNA) CEO...
Simply Wall St. via Yahoo Finance· 4 days ago(NASDAQ:MRNA) have been quite disappointing recently and CEO Stephane Bancel bears some...
Moderna (MRNA) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 days agoGood morning, everyone, and thank you for joining us on today's call to discuss Moderna's first-quarter 2024 financial results and business updates. You...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 1 day agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
Moderna Stock Jumps After Scoring an Earnings Beat. Next Up? Its RSV Shot.
Barrons.com· 2 days agoModerna reported first-quarter financial results Thursday that soundly beat Wall Street...
Moderna Focused on Cutting Costs, RSV Vaccine
Bloomberg· 2 days agoModerna Chief Executive Officer Stéphane Bancel talks about how the biotech giant is cutting costs and developing new vaccines. The drugmaker ...
